US Patent Issued to Icahn School of Medicine At Mount Sinai on Oct. 14 for "HCK inhibitors for the treatment of fibrosis and cancer" (New York Inventors)

ALEXANDRIA, Va., Oct. 21 -- United States Patent no. 12,441,746, issued on Oct. 14, was assigned to Icahn School of Medicine At Mount Sinai (New York).

"HCK inhibitors for the treatment of fibrosis and cancer" was invented by Barbara Murphy (New York), Bhaskar Das (West Nyack, N.Y.), Chengguo Wei (New York) and Li Li (New York).

According to the abstract* released by the U.S. Patent & Trademark Office: "Compounds which are oxadiazaborole derivatives are disclosed, including compounds of the following genus:The compounds are inhibitors of hematopoietic cell kinase (HCK) and exhibit anti-fibrotic and anti-proliferative effects. They are useful in the treatment of a variety of disorders, including a fibrosis or a fibrotic disease, such as re...